Thus, we tested the efficacy of two distinct STAT5A targeting lentiCRISPRv2 constructs (STAT5A-CR1 and STAT5A-CR2) through individual transduction of MV4-11 cells, and observed significantly reduced STAT5A protein levels by western blotting two weeks post-infection (Fig 1D). The gene discussed is STAT5A; the disease is infection.